Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
IT0004147952
Tue, 25.06.2024
Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals reports on its 2024 Investor Day in New York City
Clinical results and new findings of mechanism of action indicate evenamide would be uniquely effective in patients with treatment resistant schizophrenia
Leading schizophrenia experts predict earlier use of evenamide would benefit patients with inadequate response
Evena [ … ]
Tue, 18.06.2024
Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City
Three of the world’s leading key opinion leaders (KOL) in neuroscience and schizophrenia to review and present findings on Newron’s evenamide program for treatment-resistant schizophrenia
The company will host a Live-Webcast of the event, beginning at 9:00 AM EDT (2 [ … ]
Mon, 13.05.2024
Newron Pharmaceuticals S.p.A.
Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients
Further study analysis reveals significant multi-domain benefits in PANSS and Clinical Global Impression of Change (CGI-C) ratings
Benefit on efficacy measures increased over time, suggesting larger [ … ]
Tue, 30.04.2024
Newron Pharmaceuticals S.p.A.
Newron announces positive top-line results
from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
Primary endpoint and key secondary endpoint of study met; drug was well tolerated, with no safety concerns identified
Glutamatergic inhibition mechanism of action offers an innovative therapeutic option to schizoph [ … ]
Tue, 19.03.2024
Newron Pharmaceuticals S.p.A.
Newron presents 2023 financial results and provides 2024 outlook
Milan, Italy, March 19, 2024, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financ [ … ]
Fri, 15.03.2024
Newron Pharmaceuticals S.p.A.
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
EIB agrees to extend repayment dates of tranches one to three of its loan to the Company until end of 2025 and into 2026, after potentially significant pipeline milestones
Amended agreement envisages [ … ]
Thu, 14.03.2024
Newron Pharmaceuticals S.p.A.
Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares
Proceeds of up to EUR 15.0* million
Milan, Italy, March 14, 2024, 17:45 CET – Newron Pharmaceuticals S.p.A. (“Newron”, or the “Company”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients [ … ]
Thu, 04.01.2024
Newron Pharmaceuticals S.p.A.
Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)
Treatment with evenamide demonstrated significant, clinically important, progressive, sustained and long-lasting improvement on PANSS total, CGI-S and Level of Functioning (LOF)
More than 70% of patients experienced clinically im [ … ]
Fri, 29.12.2023
Newron Pharmaceuticals S.p.A.
Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide
290 patients participate at study centers in Europe, Asia and Latin America
Results from the study are expected in March 2024
Milan, Italy, December 29, 2023, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5) [ … ]
Mon, 09.10.2023
Newron Pharmaceuticals S.p.A.
Newron TRS study 6 months’ results: Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria
40% of patients no longer met TRS severity criteria
Company presented data from study in treatment resistant schizophrenia (TRS) confirming therapeutic durability and efficacy at the 36th ECNP Congress in Bar [ … ]